CSCIF (Cosciens Biopharma) Tariff Resilience Score: 7/10 (As of Jun. 27, 2026)


CSCIF Cosciens Biopharma Inc CSCIF
60 GF Score
Price $2.13
GF Value $2.39
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Tariff Resilience Score?

Cosciens Biopharma CSCIF +3.90% 60 Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus rates CSCIF with a GF Score™ of 60/100 and a GF Value™ of $2.39 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,378 Biotechnology companies, Cosciens Biopharma ranks better than 90.42% on this metric.

Cosciens Biopharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Cosciens Biopharma has Cosciens Biopharma's operations are primarily domestic, reducing tariff exposure. The company benefits from industry-specific exemptions and has shown resilience to past tariff changes. Its ability to shift suppliers and adjust pricing provides additional mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cosciens Biopharma might have Highly Resilient.

Cosciens Biopharma  (OTCPK:CSCIF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cosciens Biopharma Tariff Resilience Score Related Terms

CSCIF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Tariff Resilience Score falls into.


CSCIF
60GF Score
Cosciens Biopharma Inc CSCIF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Cosciens Biopharma (CSCIF) has a Tariff Resilience Score of 7 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Cosciens Biopharma ranks #132 out of 1378 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Cosciens Biopharma's Tariff Resilience Score too high?
Cosciens Biopharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Cosciens Biopharma's value of 7 is 75% above this industry median. Based on the distribution chart, Cosciens Biopharma ranks #132 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #132 out of 1378 companies for Tariff Resilience Score. This places Cosciens Biopharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Cosciens Biopharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.39, compared to a current price of $2.13 — trading 10.9% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $2.13 is trading 10.9% below its estimated GF Value™ of $2.39. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • Tariff Resilience Score: 7
  • GF Value™: $2.39 vs. price of $2.13 (10.9% below fair value)
  • GF Score™: 60/100 with 6 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1378)

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score

Get the complete analysis for CSCIF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price
$2.39
GF Value